Subtype selective α1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia

Bibliography

• OESTERLING JE: Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. (1996) 6:67–73.
   PubMedGoogle Scholar
• LEPOR H: Alpha adrenergic antagonists for the treatment of symptomatic BPH. Int. J. Clin. Pharmacol. Ther. Toxicol. (1989) 27:151–155.
   PubMed Web of Science ®Google Scholar
• OESTERLING JE: The origin and development of benign prostatic hyperplasia. An age- dependent process. J. Androl. (1991) 12:348–355.
   Web of Science ®Google Scholar
• JEPSEN JV, BRUSKEWITZ RC: Recent developments in the surgical management of benign prostatic hyperplasia. Urology (1998) 51:23–31.
   PubMed Web of Science ®Google Scholar
• BRUSKEWITZ RC, LARSEN EH, MADSEN PO, DORFLINGERT: 3-year followup of urinary symptoms after transure-thral resection of the prostate. J. Urol. (1986) 136:613–615.
   PubMed Web of Science ®Google Scholar
• ROOS NP, WENNBERG JE, MALENKA D et al.: Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl. J. Med. (1989) 320:1120–1124.
   PubMed Web of Science ®Google Scholar
• IMPERATO-MCGINLEY J, GAUTIER T et al.: Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J. Clin. Endocrinol. Metab. (1992) 75:1022–1026.
   PubMed Web of Science ®Google Scholar
• GORMLEY GJ, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl. J. Med. (1992) 327:1185–1191.
   PubMed Web of Science ®Google Scholar
• CAINE M: Medical management of prostatic hyperplasia. Compr. Ther. (1986) 12:21–25.
   PubMedGoogle Scholar
• CAINE M, PERLBERG S, GORDON R: The treatment ofbenign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. J. Urol. (1975) 114:564–568.
   PubMed Web of Science ®Google Scholar
• CAINE M, PERLBERG S, MERETYK S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br. J. Urol. (1978) 50:551–554.
   PubMedGoogle Scholar
• CAINE M, PERLBERG S, SHAPIRO A: Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology (1981) 17:542–546.
   Google Scholar
• COTECCHIA S, SCHWINN DA, RANDALL RR, LEFKOWITZRJ, CARON MG, KOBILKA BK: Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc. Natl. Acad. Sci. USA (1988) 85:7159–7163.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA, LOMASNEY JW, LORENZ W et al.: Molecular cloning and expression of the cDNA for a novel alpha 1- adrenergic receptor subtype. J. Biol. Chem. (1990) 265:8183–8189.
   PubMed Web of Science ®Google Scholar
• LOMASNEY JW, COTECCHIA S, LORENZ W et al.: Molecular cloning and expression of the cDNA for the alpha 1A- adrenergic receptor. The gene for which is located on human chromosome 5.1 Biol. Chem. (1991) 266:6365–6369.
   Google Scholar
• HIEBLE JP, BYLUND DB, CLARKE DE et al.: International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev. (1995) 47:267–270.
   Google Scholar
• FORRAY C, BARD J, WETZEL J et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacol-ogical properties of the cloned human alpha lc subtype. Mol. Pharmacol. (1994) 45:703–708.
   PubMed Web of Science ®Google Scholar
• LAZ T, FORRAY C, SMITH K et al.: The rat homologue of the bovine alpha lc-adrenergic receptor shows the pharmacological properties of the classical alpha lA subtype. Mol. Pharmacol. (1994) 46:414–422.
   PubMed Web of Science ®Google Scholar
• PRICE DT, LEFKOWITZ RJ, CARON MG, BERKOWITZ D, SCHWINN DA: Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol. Pharmacol (1994) 45:171–175.
   PubMed Web of Science ®Google Scholar
• HIRASAWA A, SHIBATA K, HORIE K et al.: Cloning, functional expression and tissue distribution of human alpha lc-adrenoceptor splice variants. FEBS Lett. (1995) 363:256–260.
   PubMed Web of Science ®Google Scholar
• CHANG DJ, CHANG TK, YAMANISHI SS et al: Molecularcloning, genomic characterization and expression of novel human alphalA-adrenoceptor isoforms. FEBS Lett. (1998) 422:279–283.
   PubMed Web of Science ®Google Scholar
• SHIBATA K, HIRASAWA A, MORIYAMA N, KAWABE K, OGAWA S, TSUJIMOTO G: Alpha 1 a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br. J Pharmacol (1996) 118:1403–1408.
   PubMed Web of Science ®Google Scholar
• HATANO A, TANG R, WALDEN PD, LEPOR H: The alpha-adrenoceptor antagonist properties of the enanti-omers of doxazosin in the human prostate. Eur. Pharmacol. (1996) 313:135–143.
   PubMed Web of Science ®Google Scholar
• PIASCIK MT, GUARINO RD, SMITH MS, SOLTIS EE, SAUSSYDLJ, PEREZ DM: The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J. Pharmacol. Exp. Ther. (1995) 275:1583–1589.
   PubMed Web of Science ®Google Scholar
• KENNY BA, CHALMERS DH, PHILPOTT PC, NAYLOR AM: Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol. (1995) 115:981–986.
   PubMed Web of Science ®Google Scholar
• GONG G, FORRAY C, CHIU G et al.: alc-Adrenergic antagonists and orthostatic hypotension in the rat. Faseb J. (1994) 8:A353
   Web of Science ®Google Scholar
• LEONARDI A, HIEBLE JP, GUARNERI L et al. Pharma- cological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-lL adrenoceptor in tissue selectivity, part I. J. Pharmacol. Exp. Ther. (1997) 281:1272–1283.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OSHITA M, OHMURA T et al.: Pharma-cological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. (1994) 74:572–578.
   PubMedGoogle Scholar
• FORD AP, ARREDONDO NF, BLUE DRJ et al.: RS-17053(1442-(2-cyclopropylmethoxyphenoxy)ethy11-5-chlor o-alpha, alpha-dimethy1-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol. (1996) 49:209–215.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OHMURA T, KIGOSHI S, HASHIMOTO S,OSHITA M: Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. (1990) 99:197–201.
   PubMed Web of Science ®Google Scholar
• HEDLUND H, ANDERSSON KE, EK A: Effects of prazosinin patients with benign prostatic obstruction. J. Urol. (1983) 130:275–278.
   PubMed Web of Science ®Google Scholar
• KIRBY RS, COPPINGER SW, CORCORAN MO, CHAPPLECR, FLANNIGAN M, MILROY EJ: Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br. J. Urol. (1987) 60:136–142.
   PubMedGoogle Scholar
• CHAPPLE CR, STOTT M, ABRAMS PH, CHRISTMAS TJ, MILROY EJ: A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruc-tion due to benign prostatic hyperplasia. Br. J. Urol. (1992) 70:285–294.
   PubMedGoogle Scholar
• JARDIN A, BENSADOUN H, DELAUCHE-CAVALLIER MC,STALLA-BOURDILLON A, ATTALI P: Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br. J. Urol. (1994) 74:579–584.
   PubMedGoogle Scholar
• WILDE MI, FITTON A, MCTAVISH D: Alfuzosin. A reviewof its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45:410–429.
   Google Scholar
• BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur. Urol. (1997) 31:190–198.
   PubMedGoogle Scholar
• CHAPPLE CR: Selective alpha 1-adrenoceptor antago-nists in benign prostatic hyperplasia: rationale and clinical experience. Eur. Urol. (1996) 29:129–144.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, CARTER P, CHRISTMAS TJ et al.: A threemonth double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br. J. Urol. (1994) 74:50-56. (See comments).
   Google Scholar
• GILLENWATER JY, CONN RL, CHRYSANT SG et al.:Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. (1995) 154:110–115.
   PubMed Web of Science ®Google Scholar
• LEPOR H, KAPLAN SA, KLIMBERG I et al.: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. (1997) 157:525–530.
   Google Scholar
• KAPLAN SA, D'ALISERA PM: Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J. Gerontol. A. Biol. ScL Med. ScL (1998) 53:M201–M206
   PubMed Web of Science ®Google Scholar
• KENNY BA, MILLER AM, WILLIAMSON IJ, O'CONNELL J, CHALMERS DH, NAYLOR AM: Evaluation of the pharma-cological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br. J. Pharmacol. (1996) 118:871–878.
   PubMed Web of Science ®Google Scholar
• KENNY BA, NAYLOR AM, CARTER AJ, READ AM, GREENGRASS PM, WYLLIE MG: Effect of alpha-1 adreno-ceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology (1994) 44:52–57.
   PubMed Web of Science ®Google Scholar
• TSUNO0 M, SHISHITO A, SOESHI Y, KOBORI M, SHIMOYAMA M: Phase I clinical trial of YM617, a new al-adrenoceptor antagonist- First report: A single oral dose of conventional formulation in healthy male subjects. Rinsho Iyaku (1990) 6:2503–2528.
   Google Scholar
• CHAPPLE CR, BAERT L, THIND P, HOFNER K, KHOE GS, SP: Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur. Urol. (1997) 32:462–470.
   Google Scholar
• DE MEY C: Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur. Urol. (1998) 34\(Suppl. 2):18–28.
   Google Scholar
• LEPOR H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology (1998) 51:892–900.
   Google Scholar
• KATWALA SP, MILICIC IP, HANCOCK AA, BRUNE ME: Differential effects of various alpha-1 adrenoceptor antagonists on urogenital and vascular smooth muscle in vivo. Faseb (1996):10
   PubMedGoogle Scholar
• MICHEL MC, BRESSEL HU, MEHLBURGER L, GOEPEL M: Tamsulosin: real life clinical experience in 19,365 patients. Eur. Urol. (1998), 34\(Suppl. 2):37–45.
   Google Scholar
• ANDERSSON KE, LEPOR H, WYLLIE MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate (1997) 30:202–215.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: The concept of uroselectivity. Eur. Urol. (1998) 33 (Suppl. 2): 7–11.
   Google Scholar
• IMAGAWA J, AKIMA M, SAKAI K: In vivo experiments for the evaluation of alpha 1-adrenoceptor antagonistic effects of SGB-1534 on canine urethra. Eur. J Pharmacol (1989) 167:167–172.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI M, SUDOH K, INAGAKI 0, UCHIDA W, HONDA K: Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. J. Auton. Pharmacol. (1992) 12:263–268.
   PubMedGoogle Scholar
• BRESLIN D, FIELDS DW, CHOU TC et al: Medical manage-ment of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. (1993) 149:395–399.
   PubMed Web of Science ®Google Scholar
• BRUNE ME, BUCKNER SA, POLAKOWSKI J, KERWIN JF, HANCOCK A: Pharmacological antagonism of a adrenergic agonist induced increases in canine intrau-rethral pressure in vivo. Drug Dev. Res. (1995) 34:267–275.
   Web of Science ®Google Scholar
• BLUE D, FORD A, MORGANS D, PADILLA F, CLARKE D: Preclinical pharmacology of a novel a la/a1L-adrenoceptor antagonist, RS 100975. Neurourol. Urodyn. (1996) 15:345–346.
   Google Scholar
• LEFEVRE-BORG F, LECHAIRE J, O'CONNOR SE: In vivo uroselectivity of alfusozin compared to prazosin and terazosin. Br. J Pharmacol (1992) 106:84P
   Web of Science ®Google Scholar
• TESTA R, SIRONI G, COLOMBO D, GRETO L, LEONARDI A: Rec15/2739, a new al adrenoceptor antagonist selective for the lower urinary tract: In vivo studies. Neurol Urodyn. (1994) 13:471–472.
   Google Scholar
• VARGAS HM, GORMAN AJ: Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci. (1995) 57:2291–2308.
   PubMed Web of Science ®Google Scholar
• SULLIVAN J, WILLIAMS M: a-1 adrenoceptors as targets for therapeutic agents in urology. IUPHAR satellite symposium, 23–24 July, Palais de Congres, Paris, France. ID Weekly Highlights (1998) 8:33–37.
   Google Scholar
• HIEBLE J, RUFFOLO RR, JR: Recent advances in the identification of al and a2-adrenoceptor subtypes: therapeutic implications. Exp. Opin. Invest. Drugs (1997) 6:367–387.
   PubMedGoogle Scholar
• LEFEVRE-BORG F, GEORGE P, O'CONNOR SE et al: SL-89.051: a novel alphal-adrenoceptor antagonist which shows preferential effects on the lower urinary tract. Proc. Br. Pharmacol. Soc. (1995) 114:419P
   Google Scholar
• GEORGE P, BORG F, O'CONNOR S et al.: Uroselectivealphal-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur. J. Med. Chem (1995) 30:299s–310s.
   Google Scholar
• BLUED, ZHU QM, ISOM P, YOUNG S, LARSON M, CLARKE D: Effect of al adrenoceptor (al-AR) antagonists in dog prostate/blood pressure models. Faseb j (1999) 10:A425.
   Google Scholar
• BUCKNER S, IRELAND L, KANG C, MEYER M, HANCOCK A, KERWIN, JR. J: A-131701, a new selective antagonist for adrenoreceptors. The Pharmacologist (1997) 39:44
   Google Scholar
• MEYER MD, ALTENBACH RJ, BASHA FZ et al.: Synthesis and pharmacological characterization of 3[-((3aR,9bR)-cis-6-methoxy-2, 3, 3a, 4,5,9b -hexahydro-1H-benz[e] isoindo1-2-yfiethyllpyrido-[3', 4':4,5]thieno[ 3,2-d]pyrimidine-2,4 (1H,311)-dione (A-131701): a uroselective alpha lA adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia. J. Med. Chem. (1997) 40:3141–3143.
   PubMed Web of Science ®Google Scholar
• MEYER MD, ALTENBACH RJ, BASHA FZ et al.: Discovery of novel potent and selective alA adrenoceptor antagonists for the symptomatic treatment of benign prostatic hyperplasia (BPH). 213th National Meeting of the American Chemical Society. San Francisco, CA (1997).
   Google Scholar
• ABOUD R, SHAFII M, DOCHERTY JR: Investigation of the subtypes of alpha 1-adrenoceptor mediating contrac-tions of rat aorta, vas deferens and spleen. Br. J. Pharmacol. (1993) 109:80–87.
   PubMed Web of Science ®Google Scholar
• BUCKNER SA, OHEIM KW, MORSE PA, KNEPPER SM, HANCOCK AA: Alpha 1-adrenoceptor-induced contrac-tility in rat aorta is mediated by the alpha 1D subtype. Eur. Pharmacol. (1996) 297:241–248.
   PubMed Web of Science ®Google Scholar
• HANCOCK A, BRUCKNER S, BRUNE M et al.: Pharma-cological characterization of A-131701, a novel Alphal-adrenocepto antagonist selective for AlphalA-and AlphalD-compared to AlphalB-adrenoceptors. Drug Dev. Res. (1998) 44:140–162.
   Web of Science ®Google Scholar
• VERFURTH F, ERDBRUEGGER W, MICHEL M: Comparison of Rec 15-2739 and terazosin alpha-1-adrenoceptor subtype affinities. Br. J. Pharmacol (1995) 116:208P
   Web of Science ®Google Scholar
• HANCOCK A, BRUNE M, WITTE D et al.: Actions of A-131701, a novel, selective antagonist for alpha-lA compared with alpha-1B adrenoceptors on intraure-thral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. J. Pharmacol. Exp. Ther. (1998) 285:628–642.
   PubMed Web of Science ®Google Scholar
• SMITHKLINE BEECHAM PLC.: Striving to make peolpes lives better. Annual Report (1995).
   Google Scholar
• Scrip (1996) 2129:25.
   Google Scholar
• Scrip (1998) 2322:9.
   Google Scholar
• Scrip (1999) 2424:5.
   Google Scholar
• LEONARDI A: Synthesis and pharmacological evalua-tion of new 411-1-benzopyran derivatives, uroselective a 1 -adrenoceptor antagonists. 13th International Symposium on Medicinal Chemistry. Paris, France, (1994).
   Google Scholar
• MOTTA G: Structural modification at the basic moiety of REC 15/2739, a novel uroselective al-adrenoceptor antagonist. 113th International Symposium on Medicinal Chemistry. Paris, France, (1994).
   Google Scholar
• TESTA R, TADDEI C, POGGESI E et al.: Rec 15/2739 (SB 216469) a novel prostate selective al-adrenoceptor antagonist. Pharmacol Comm. (1995) 6:79–86.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, VERFURTH F, NOBLE AJ, COULDWELL CJ, MICHEL MC: The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor. Br. J. Pharmacol. (1996) 119:1093–1100.
   PubMed Web of Science ®Google Scholar
• TESTA R, GUARNERI L, TADDEI C et al.: Functionalantagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol Exp. Ther. (1996) 277:1237–1246.
   PubMed Web of Science ®Google Scholar
• JAPAN TOBACCO INC.: Company Communication (1998).
   Google Scholar
• MURAMATSU I, TAKITA M, SUZUKI F, MIYAMOTO S, SAKAMOTO S, OHMURA T: Subtype selectivity of a new alpha 1-adrenoceptor antagonist, JTH-601: comparison with prazosin. Eur. J. Pharmacol (1996) 300:155–157.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, TANIGUCHI T, MURATA S, OKADA K, MOIYAMA N, YAMAZAKI S, MURAMATSU I: New alphal-adrenoceptor antagonist, JHT-601, shows more than 10 times higher affinity for human prostates than arteries. J. Urol (1999) 161:1350–1354.
   PubMed Web of Science ®Google Scholar
• YAMADA S, OHKURA T, KIMURA R, KAWABE K: In vivo receptor binding of novel alphal-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sci. (1998) 62:1585–1589.
   PubMed Web of Science ®Google Scholar
• WETZEL J, MIA() S, FORRAY C, BORDEN L, BRANCHEK T, GLUCHOWSKI C: Discovery of alpha la-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J. Med. Chem. (1995) 38:1579–1581.
   PubMed Web of Science ®Google Scholar
• MARZABADI MR, WETZEL JM, CHIU, G et al.: Design andsynthesis of novel dihydropyridine alpha-la antago-nists. 211th National Meeting of the American Chemical Society. New Orleans, LA, USA (1996).
   Google Scholar
• BOER R, GRASSEGGER A, SCHUDT C, GLOSSMANN H: (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur. J Pharmacol (1989) 172:131–145.
   PubMed Web of Science ®Google Scholar
• WONG WC, CHIU G, WETZEL JM et al.: Identification of a dihydropyridine as a potent alphala adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate. J. Med. Chem. (1998) 41:2643–2650.
   PubMed Web of Science ®Google Scholar
• NAGARATHNAM D, LAGU B, CHIU G et al.: Design, synthesis and evaluation of dihydropyrimidinones as alphala selective antagonists: 2. Structure-activity relationships of SNAP 5582 analogs. 214th National Meeting of the American Chemical Society. Las Vegas, NV, USA (1997).
   Google Scholar
• WONG WC, ZHANG J, LAGU B et al.: Alpha-la adreno-ceptor selective antagonists as novel agents for treating benign prostatic hyperplasia. 217th National Meeting of the American Chemical Society. Anaheim, CA, (1999).
   Google Scholar
• CHEN T, O'MALLEY S, NAGARATHNAM D et al.: In vitro pharmacology of SNAP 6991: an cc1A-adrenergic selective antagonist. Faseb J. (1999) 13:A150.3
   Google Scholar
• BROTEN T, RANSOM R, SCOTT A et al.: In vivo pharma-cology of SNAP 6991 (L-780,945), an Oa selective adrenergic receptor antagonist. Faseb J. (1999) 13:A150.7
   Google Scholar
• HARUTA K, BABA A, AKIMA M, KOGA T, SHIRAKI Y, SAKAI K: Alpha-adrenoceptor antagonistic effects and antihypertensive activity of SGB-1534 in conscious normotensive and deoxycorticosterone acetate (DOCA)-salt hypertensive dogs: comparison with prazosin. Arch. Int. Pharmacodyn. Ther. (1989) 299:169–184.
   PubMedGoogle Scholar
• NERENBERG JB, ERB JM, THOMPSON WJ et al.: Design and synthesis of N-alkylated saccharins as selective alpha-la adrenergic receptor antagonists. Bioorg. Med. Chem Lett. (1998) 8:2467–2472.
   PubMed Web of Science ®Google Scholar
• DREWRY DH: Alpha-lA antagonists for Benign prostatic hyperplasia. 212th National Meeting of the American Chemical Society. Orlando, FL, USA (1996).
   Google Scholar
• ADKISON KK, HALM KA, SHAFFER JE, DREWRY D, SINHABABU AK, BERMAN J: Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parame-ters. Pharm. Biotechnol (1998) 11:423–443.
   Google Scholar
• LIU S, RASMUSSON R, WANG S, CAMPBELL D, SHAFFER J, STRAUSS H: GG818: A novel drug that inhibits cardiac IKR with high specificity. Biophysical Journal (1998) 74:A207.
   Web of Science ®Google Scholar
• Scrip (1996) 2179:18.
   Google Scholar
• SHIBATA K, FOGLAR R, HORIE K et al.: KMD-3213, a novel, potent, alpha la-adrenoceptor-selective antago-nist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. MoL Pharmacol. (1995) 48:250–258.
   PubMed Web of Science ®Google Scholar
• MORIYAMA N, AKIYAMA K, MURATA S eta].: KMD-3213, a novel alphalA-adrenoceptor antagonist, potently inhibits the functional alphal-adrenoceptor in human prostate. Eur. J. Pharmacol (1997) 331:39–42.
   Google Scholar
• YAMAGISHI R, AKIYAMA K, NAKAMURA S et al.: Effect of KMD-3213, an alpha la-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur.j Pharmacol (1996) 315:73–79.
   PubMed Web of Science ®Google Scholar
• OHKURA T, YAMADA S, KIMURA R, AKIYAMA K, IIZUKA K, KAWABE K: Tissue selectivity of in vivo alpha-1-adrenoceptor binding of KMD-3213, a novel alpha-lA adrenoceptor antagonist in rats. Neurourol Urodyn. (1997) 16:493–495.
   Google Scholar
• AKIYAMA K, TATEMICHI S, HORA M et al.: Uro-selectivity and long-lasting action of KMD-3213, an alpha-1A-adrenoceptor antagonist, in a novel rat model. Neurourol. Urodyn. (1997) 16:492–493.
   Google Scholar
• ELWORTHY TR, FORD AP, BANTLE GW, et al.: N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists. J. Med. Chem. (1997) 40:2674–2687.
   Google Scholar
• HOFFMAN LA ROCHE: Company communication. (1995).
   Google Scholar
• WILLIAMS T, BLUE D, MORGANS D et al.: Pharmacology of Ro 70-0004 (RS-100975), a novel cc1A-adrenoceptor (AR)-selective antagonist. Br. J. Pharmacol. (1997) 120:106P.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TJ, BLUE DR, DANIELS DV et al.: In vitro alphal-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alphalA-adrenoceptor selective antagonists. Br. J. Pharmacol. (1999) 127:252–258.
   PubMed Web of Science ®Google Scholar
• BLUE D, FORD A, MORGANS D, WILLIAMS T, ZHU Q-M, CLARKE D: The conscious 'reflex-compromised rat: a model for evaluating the hypotensive potencies of the a1-adrenoceptor antagonists prazosin, tamsulosin and Ro 70-0004. Br. J. Pharmacol (1997) 120:107P
   PubMed Web of Science ®Google Scholar
• KENNY BA, NAYLOR AM, GREENGRASS PM et al: Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens. Br. J. Pharmacol. (1994) 111:1003–1008.
   PubMed Web of Science ®Google Scholar
• KENNY B, BALLARD S, BLAGG J, FOX D: Pharma-cological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. (1997) 40:1293–1315.
   PubMed Web of Science ®Google Scholar
• KUO GH., PROUTY CP., MURRAY W et al: Synthesis and structure-activity relationships of phenylpiperazine derivative: A new series of potent and selective a-1A adrenergic receptor antagonist. 218th National Meeting American Chemical Society. New Orleans, LA, USA (1999).
   Google Scholar
• MCCONNELL JD, BARRY MJ, BRUSKEWITZ RC: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin. Pract. Guide]. Quick. Ref Guide. Gin. (1994):1–17.
   Google Scholar
• FURUYA S, KUMAMOTO Y, YOKOYAMA E, TSUKAMOTO T, IZUMI T, ABIKO Y: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. (1982) 128:836–839.
   PubMed Web of Science ®Google Scholar
• BARRY MJ, FOWLER FJJ, O'LEARY MP et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. (1992) 148:1549–1557.
   Google Scholar
• ABRAMS PH, FARRAR DJ, TURNER-WARWICK RT, WHITESIDE CG, FENELEY RC: The results of prostatec-tomy: a symptomatic and urodynamic analysis of 152 patients. J. Urol. (1979) 121:640–642.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JT, NORDLING J, WALTER S: Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings. Scand. J. Urol. Nephrol. (1979) 13:229–236.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JT, NORDLING J: Prostatism. II. The correla-tion between cysto-urethroscopic, cystometric and urodynamic findings. Scand. J. Urol. Nephrol. (1980) 14:23–27.
   PubMed Web of Science ®Google Scholar
• JORGENSEN JB, JENSEN KM, MOGENSEN P: Significance of predominantly irritative symptomatology before a prostatic operation. J. Urol. (1990) 143:739–741.
   PubMed Web of Science ®Google Scholar
• NIELSEN KK, ANDERSEN CB, PETERSEN LK, OXLUND H, NORDLING J: Morphological, stereological, and biochemical analysis of the mini-pig urinary bladder after chronic outflow obstruction and after recovery from obstruction. Neurourol. Urodyn. (1995) 14:269–284.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Prostatic and extraprostatic alpha-adrenoceptors-contributions to the lower urinary tract symptoms in benign prostatic hyperplasia. Scand.J. Urol. Nephrol. Suppl. (1996) 179:105–111.
   PubMedGoogle Scholar
• PERLBERG S, CAINE M: Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. Urology (1982) 20:524–527.
   Google Scholar
• CHAPPLE CR, SMITH D: The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br. J. Urol. (1994) 73:117-123.(See comments).
   Google Scholar
• WITJES WP, ROSIER FW, DE WILDT MJ, VAN IERSEL MP, DEBRUYNE FM, DE LA ROSETTE JJ: Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J. Urol. (1996) 55:1117–1123.
   Google Scholar
• LEPOR H, NIEDER A, FESER J, O'CONNELL C, DIXON C: Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology (1997) 49:476–480.
   PubMed Web of Science ®Google Scholar
• BARRY MJ, COCKETT AT, HOLTGREWE HL, MCCONNELL JD, SIHELNIK SA, WINFIELD HN: Relationship of symptoms of prostatism to commonly used physio-logical and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol. (1993) 150:351–358.
   PubMed Web of Science ®Google Scholar
• CHANCELLOR MB, RIVAS DA, KEELEY FX, LOTFI MA, GOMELLA LG: Similarity of the American Urological Association Symptom Index among men with benign prostate hyperplasia (BPID, urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br. J. Urol. (1994) 74:200–203.
   PubMedGoogle Scholar
• CHANCELLOR MB, BLAIVAS JG, KAPLAN SA, AXELROD S: Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow. J. Urol. (1991) 145:810–812.
   PubMed Web of Science ®Google Scholar
• SCHAFER W, RUBBEN H, NOPPENEY R, DEUTZ FJ: Obstructed and unobstructed prostatic obstruction. World J. Urol. (1989), 6:198–203.
   Web of Science ®Google Scholar
• REYNARD J, ABRAMS P: Symptoms and symptom scores in BPH. Scand.j Urol Nephrol. Suppl. (1994) 157:137–145.
   PubMedGoogle Scholar
• NEAL DE, STYLES RA, POWELL PH, RAMSDEN PD: Relationship between detrusor function and residual urine in men undergoing prostatectomy. Br. J. Urol. (1987) 60:560–566.
   PubMedGoogle Scholar
• ROLLEMA HJ, VAN MASTRIGT R: Improved indication and followup in transurethral resection of the prostate using the computer program CLIIVI: a prospective study. J. Urol. (1992) 148:111–115.
   PubMed Web of Science ®Google Scholar